On October 22nd, "I think it is a necessity to pursue the valuation of biomedical enterprises and innovative enterprises since last year." Chen Qiyu, executive director and co-president of Fosun International and chairman of Fosun Medical, said in an interview. Because everyone wants to find explosive opportunities, the industry does have a lot of explosive opportunities.

　　He mentioned that the IT industry and the BT (biomedical) industry have always been two hot spots in the development of global high-tech industries. From China's point of view, he believes that the Internet industry has been developing rapidly for nearly 20 years. With the listing of a series of Internet technology companies last year, the changes in the performance and valuation of these companies have made investors realize that the industry is beginning to have investment risks. Compared with the Internet, in the past 20 years, the biomedical industry has created a huge gap, which also means a broader investment space.

　　“It can be said that the innovation and development of China’s BT industry is about 10 to 15 years later than the Internet. Most of the companies may start their business around 2010.” Chen Qiyu said that at the same time, the innovation cycle of the biomedical industry is different. From the time of creation to the birth of a product, it may take 8 years, 10 years, or even 15 years and 20 years. After a long period of cultivation, a number of high-quality enterprises began to emerge.

　　Moreover, he said that the biomedical industry can accommodate growing companies far more than the IT industry. "The Internet industry sometimes has winners, one or two companies on the track, but a cancer in the BT industry may evolve. A lot of heavy products, more opportunities." Coupled with the huge adjustment of China's pharmaceutical industry policy, the return of top talents overseas, etc., belongs to "the right place and the right people", Chen Qiyu believes that capital is a fire at this time.

　　At the "2019 Fosun Global Health VC Investors Summit" hosted by Fosun Health, Fosun joined forces with 11 of the world's top VC funds from the United States, the United Kingdom, and Israel to establish the "Global Healthcare Innovation Investment Alliance." VC investment is the vane of industrial trends and technological innovations. Research teams with innovative capabilities and cutting-edge research have always been favored by VC.

　　Guo Guangchang, chairman of Fosun International, said that Fosun, as a global company driven by Science and Technology, and the world's leading VC fund, established the “Global Health VC Fund Investment Alliance” to further promote the pharmaceutical and health industry, government, academic institutions, The cooperation and exchange between practitioners and VC investors is an innovation and opening up and resource sharing.

　　Although the biomedical industry is sought after, Chen Qiyu said that some projects have a certain valuation bubble, just like the previous Internet industry. But he feels that without such a push, the pharmaceutical industry will not develop so fast. "I feel that you only have to insist, one is time to persist, the second is to insist on the essence of this project, I think there will be gains and benefits in the end."

　　One of the stickings of Fosun Pharma is R&D investment. Last year, it invested about 2.5 billion yuan, an increase of more than 60%. In this regard, Chen Qiyu said that in the first half of this year, their R&D investment continued to grow. “From the current point of view, R&D is mainly improving to innovative biopharmaceuticals. I think there will be some sustained growth in the future.” He introduced the company's considerations from two dimensions: First, the proportion of R&D investment in sales revenue needs to remain constant. Intensity, while taking into account the shareholder returns of listed companies; Second, the company's growth pipeline must be determined to invest.

　　Not only in research and development, Fosun Pharma also joined hands with Professor Xu Tian, ​​Vice President of Xihu University, and established the Biomedical Science Incubation Platform Fosun Lingzhi (Shanghai) Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Fuxing Lingzhi”). Shanghai was completed and opened.

　　Wu Yifang, president and CEO of Fosun Pharma, said that Fosun Lingzhi is one of the innovative models of Fosun Pharma. It is a “deep incubation” platform for global medical innovation technology, and is a venture partner in various fields such as disease prevention and treatment. The way to accelerate the transformation of scientific and technological achievements through the incubation platform, accelerate the listing of global innovative products.

　　It is reported that Fosun Lingzhi will focus on precision medicine, tumor immunology, stem cell and regenerative medicine, intestinal flora, synthetic biology, POCT, artificial intelligence and other sub-fields, and is committed to technical breakthroughs based on clinical unmet needs. And product development. Jinghao Technology is the first incubator project of Fosun Lingzhi. Xu Tian revealed that it is expected that three new companies will soon be hatched. (Sina Finance Xu Wei)

　　Source: Sina Finance Editor: Zhang Haiying